These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28711312)

  • 21. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) : The androgen receptor-independent active agent in the therapeutic sequence].
    König F; Strauß A; Johannsen M; Mommsen C; Fricke E; Klier J; Mehl S; Pfister D; Sahlmann CO; Werner A; Goebell PJ
    Urologe A; 2020 Jan; 59(1):53-64. PubMed ID: 31598745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.
    Rodriguez-Vida A; Torregrosa MD; Pinto Á; Climent MÁ; Olmos D; Carles J
    Clin Transl Oncol; 2018 Jun; 20(6):679-686. PubMed ID: 29098556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Radium 223 in castration resistant prostate cancer.].
    Loizaga-Iriarte A; Camargo Ibargarai I; Senarriaga-Ruiz de la Illa N; Lacasa-Viscasillas I; Unda-Urzaiz M
    Arch Esp Urol; 2018 Sep; 71(8):696-703. PubMed ID: 30319129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Kim SI; Szeto AH; Morgan KP; Brower B; Dunn MW; Khandani AH; Godley PA; Rose TL; Basch EM; Milowsky MI; Whang YE; Crona DJ
    PLoS One; 2021; 16(6):e0253021. PubMed ID: 34153052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
    Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
    Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
    Dorff TB; Gross ME
    Am Soc Clin Oncol Educ Book; 2015; ():e270-3. PubMed ID: 25993185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
    Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
    Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland Ø; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D
    Eur Urol; 2016 Nov; 70(5):875-883. PubMed ID: 27344296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of Palliative
    Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T
    J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer.
    Dandapani SV; Wong J; Twardowski P
    Cancer Biother Radiopharm; 2020 Sep; 35(7):490-496. PubMed ID: 32762539
    [No Abstract]   [Full Text] [Related]  

  • 33. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
    Shore ND
    Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
    Shirley M; McCormack PL
    Drugs; 2014 Apr; 74(5):579-86. PubMed ID: 24610703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
    Armstrong AJ; Gupta S; Healy P; Kemeny G; Leith B; Zalutsky MR; Spritzer C; Davies C; Rothwell C; Ware K; Somarelli JA; Wood K; Ribar T; Giannakakou P; Zhang J; Gerber D; Anand M; Foo WC; Halabi S; Gregory SG; George DJ
    PLoS One; 2019; 14(5):e0216934. PubMed ID: 31136607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT
    Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.
    Iizuka J
    Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():16-23. PubMed ID: 30489033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Four years of clinical experience with Radium-223 for the treatment of castration-resistant prostate cancer.
    Álvarez Pérez RM; Delgado García A; García Martínez S; Sanz Viedma S; Palacios Gerona H; Pajares Vinardel M; Jiménez-Hoyuela García JM
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(5):298-304. PubMed ID: 31362912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
    Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
    Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
    Baldari S; Boni G; Bortolus R; Caffo O; Conti G; De Vincentis G; Monari F; Procopio G; Santini D; Seregni E; Valdagni R
    Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.